innovation for industry
Articles ＆ files | Focus | Article
Peps enables large scale clinical testing using MS-based proteomics, and the discovery of new biomarkers.
PepS is a highly reliable and robust microfluidic device that rapidly processes whole blood samples at the patient's bedside, delivering deferred downstream MS-based proteomics analyses.
The first prototype was released in 2019. Researchers are currently discussing further collaborations with industrials working within the proteomic environment.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.